image showing signpost with text saying we are here to support your evidence-based product generation

A fee-based consultancy service to developers of:

  • pharmaceuticals
  • biopharmaceuticals
  • medical devices
  • diagnostics

We work with you in the early stages of product development. Our mission is to encourage you to consider the relative clinical and cost effectiveness of your products. These considerations can then inform your development strategy.

Make an enquiry

 

Our advice helps you prepare for NICE evaluations and supports discussions with payers and commissioners to enable market access.

Engaging with scientific advice can:

  • help you develop evidence that demonstrates the value of your product
  • provide detailed feedback on your clinical, economic development and evidence generation plans
  • provide insights from NICE-appointed experts
  • advise on the advantages and disadvantages of different options
  • help to integrate cost-effectiveness considerations into your evidence generation plans
  • help companies understand health technology assessments, and the perspective of decision makers, at our educational seminars and events.

To find out more about our wide range of services, choose from one of the options below and read our frequently asked questions.

You can find out more about the team on our biographies page.

AdviSeMe prize 

The AdviSeME prize is now closed. We are currently reviewing applicants and finalists will be notified by 5 December 2017. Winners will be announced and displayed here by late January 2018.


Image of a pill

Pharmaceutical products

Standard scientific advice

Detailed advice from NICE and a panel of appointed experts.

 

NICE-MHRA scientific advice

Joint regulatory advice from the Medicines and Healthcare products Regulatory Agency and NICE Scientific Advice.

 

HTA-EMA scientific advice

Advice from the European Medicines Agency in parallel with NICE and other European Health Technology Assessment bodies.

 

Advice for small and medium-sized companies

A concise, more affordable version of our standard advice process.

Read our FAQs
Image of a heart beat

Devices and diagnostics

Medtech Early Technical Assessment (META) tool

An affordable platform to help product developers understand what evidence is needed to make a convincing case to payers and commissioners for their technology.

 

Standard scientific advice

Detailed advice from NICE and a panel of appointed experts.

 

Advice for small and medium-sized companies

A concise, more affordable version of our standard advice process.

 

NICE-FDA scientific advice

Advice from the United States’ Food and Drug Administration PCTF in parallel with NICE. Contact us for further information.

Read our FAQs
Image of a seminar

Seminars, events and speaking engagements

9 November 2017 - London

The Organisation for Professionals in Regulatory Affairs (TOPRA) Annual Symposium

Our Senior Technical Advisor, Dr Elangovan Gajraj, will provide an insightful introduction into the processes and methodologies at NICE and the HTA.

9 November 2017 - London

Fifth annual European Advanced Therapies Investor Day organised by the Alliance for Regenerative Medicine

Our Technical Advisor, Pilar Pinilla Dominguez, will be participating on the panel for health technology assessment and access for ATMPs. 

18 November 2017 - Amsterdam

European Patient Advocacy Forum

Our Technical Advisor, Pilar Pinilla Dominguez, will be participating on the forum for empowering advocacy through data generation: facilitating medicine approval and access. The meeting is organised by BioMarin.

5 December 2017 - Berlin

International Medical Device Payer & HTA Forum

Dr Eva Barkauskaite, our Technical Analyst, will be delivering a presentation on the scientific advice services that NICE offers to medtech developers and manufacturers.

See all events